



ADMINISTRATIVE POLICY STATEMENT

Ohio Medicaid

Policy Name & Number	Date Effective
Pharmacogenomics-CYP Gene Testing-OH MCD-AD-1342	04/01/2024-01/31/2025
Policy Type	
ADMINISTRATIVE	

Administrative Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Administrative Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Administrative Policy Statement. If there is a conflict between the Administrative Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

A. Subject.....	2
B. Background.....	2
C. Definitions	2
D. Policy	2
E. Conditions of Coverage.....	3
F. Related Policies/Rules.....	3
G. Review/Revision History.....	4
H. References.....	4

A. Subject

Pharmacogenomics – CYP Gene Testing

B. Background

Pharmacogenomics is an area of precision medicine that provides information about an individual's genes, influencing therapeutic strategies, and assessing the likelihood of benefit or toxicity to a given drug. This form of medication management has been evaluated in a variety of clinical scenarios. As pharmacogenomics expands and laboratories offering testing proliferate, the value of a given test in terms of patient benefit may be obscured by multiple contributing factors, including exaggerated public marketing claims, inconsistencies in test standardization, continued patient variation in response to prescribed medication, incomplete knowledge of drug metabolism, and limitations in regulatory oversight. To manage these challenges, the clinical validity and clinical utility of a specific gene or biomarker with a specific drug target should demonstrate improvement in patient outcomes.

C. Definitions

- **Clinical Utility** – The likelihood that a test will, by prompting an intervention, result in an improved health outcome.
- **Clinical Validity** – The accuracy of a test for a given clinical outcome.
- **Unbundling** – HCPCS/CPT codes should be reported only if all services described by the code are performed. Multiple codes should not be reported if a single code exists that describes the services performed. The codes include all services usually performed as part of the procedure as a standard of medical/ surgical practice and should not be separately reported simply because codes exist for the services.

D. Policy

I. General Guidelines

- A. Biomarker testing with uncertain clinical significance in MCG will be considered experimental and investigational.
- B. Unbundling of codes in a panel is an incorrect billing practice and will result in payment recovery.
- C. Any drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply used in or directly related to the diagnosis, evaluation, or treatment of a disease, injury, illness, or other health condition which CareSource determines in its sole discretion to be experimental or investigational is not covered by CareSource.

- II. Based on review of existing evidence, there are currently no clinical indications for the high-volume tests below, and the current role remains uncertain. Therefore, CareSource considers these requests experimental and investigational. This is not an all-inclusive list.

CPT® Codes	Testing Examples
81225 - CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)	Genecept Assay, OneOme

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

81226 - CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)	RightMed, PGxOnePlus, CQuentia, IDGenetix, PROOVE, GARSPREDX, SureGene, PharmacoDx
81227 - CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)	
81230 - CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)	
81291 - MTHFR (5, 10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	

III. CareSource applies coding edits to medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. Proper billing and submission guidelines must be followed, including the following:

- A. Use of industry standard, compliant codes on all claims submissions, including CPT codes and/or HCPCS codes.
- B. Services considered to be mutually exclusive, incidental to, or integral to the primary service rendered are not allowed additional payment.
- C. Proprietary panel testing requires evidence-based documentation of medical necessity.
- D. Submission of the most accurate and appropriate CPT/HCPCS code(s) for the product or service being provided, including coding to the highest level of specificity.

IV. CareSource considers the following not medically necessary (not an all-inclusive list):

- A. Pharmacogenomic testing or screening in the general population.
- B. A non-covered test billed by using unlisted procedure codes.
- C. The use of multi-gene panels for genetic polymorphisms, including, but not limited to, pain management, cardiovascular drugs, anthracyclines, or polypharmacy for evaluating drug-metabolizer status (ie, SureGene Test, PharmacoDx).
- D. Tests considered screening in the absence of clinical signs/symptoms of disease.
- E. Tests that do not confirm new data for decision making but confirm a known diagnosis or information.
- F. Tests to determine risk for developing a disease or condition.
- G. Tests without diagnosis-specific indications.
- H. Tests performed to ensure a tissue specimen matches an individual.

E. Conditions of Coverage

Codes referenced in this policy are for informational purposes only. Inclusion or exclusion of any code(s) does not guarantee coverage.

F. Related Policies/Rules

Overpayment Recovery

Experimental and Investigational Items and Services

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

G. Review/Revision History

	DATE	ACTION
Date Issued	04/26/2023	Approved at Committee.
Date Revised	01/31/2024	Removed 0345U from D.II. Updated references. Approved at Committee.
Date Effective	04/01/2024	
Date Archived	01/31/2025	This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.

H. References

1. Clinical laboratory improvement amendments (CLIA). Centers for Disease Control and Prevention. Reviewed January 16, 2024. Accessed January 23, 2024. www.cdc.gov
2. *Clinical Use of Pharmacogenetic Testing in Prescribing Psychotropic Medications for Children and Adolescents*. American Academy of Child & Adolescent Psychiatry; 2020. Accessed January 23, 2024. www.aacap.org
3. Clinical utility evaluation: APOE genetic testing for Alzheimer Disease. Hayes; 2018. Updated May 18, 2022. Accessed January 23, 2024. www.hayesinc.com
4. Clinical utility evaluation: genetic testing for common forms of hereditary thrombophilia in adults with unprovoked venous thromboembolism. Hayes; 2019. Updated June 21, 2022. Accessed January 23, 2024. www.evidence.hayesinc.com
5. Clinical utility evaluation: genetic testing for common forms of hereditary thrombophilia in pediatric patients with unprovoked venous thromboembolism. Hayes; 2019. Updated June 21, 2022. Accessed January 23, 2024. www.evidence.hayesinc.com
6. Clinical utility evaluation: genetic testing for factor V Leiden in women with unexplained recurrent pregnancy loss. Hayes; 2018. Updated October 24, 2022. Accessed January 23, 2024. www.hayesinc.com
7. Clinical utility evaluation: *MTHFR* genetic testing for hypertension. Hayes; 2023. Accessed January 23, 2024. www.hayesinc.com
8. Clinical utility evaluation: *MTHFR* genetic testing for nondevelopmental psychiatric disorders. Hayes; 2023. Accessed January 23, 2024. www.hayesinc.com
9. Clinical utility evaluation: *MTHFR* genetic testing for pregnancy complications. Hayes; 2023. Accessed January 23, 2024. www.hayesinc.com
10. Clinical utility evaluation: *MTHFR* genetic testing for severe *MTHFR* enzyme deficiency. Hayes; 2017. Updated September 29, 2023. Accessed January 23, 2024. www.hayesinc.com
11. Clinical utility evaluation: *MTHFR* pharmacogenetic genotyping for altering drug treatment. Hayes; 2017. Updated May 23, 2021. Accessed January 23, 2024. www.hayesinc.com
12. Clinical utility evaluation: pharmacogenetic and pharmacogenomic testing for opioid treatment for pain in adults – selected single-gene variants and pharmacogenomic panels. Hayes; 2019. Updated October 26, 2022. Accessed January 23, 2024.

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

- www.evidenced.hayesinc.com
13. Clinical utility evaluation: pharmacogenetic and pharmacogenomic testing to improve outcomes related to opioid use disorder. Hayes; 2020. Updated June 30, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
 14. Clinical utility evaluation: pharmacogenomic testing for attention-deficit/hyperactivity disorder. Hayes; 2022. Updated March 31, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
 15. Clinical utility evaluation: pharmacogenomic testing of selected mental health conditions. Hayes; 2021. Updated December 1, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
 16. Clopidogrel pharmacogenetics-CYP2C19 gene: A-0631. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
 17. Deoxyribonucleic acid (DNA) fact sheet. National Human Genome Research Institute. Updated August 24, 2020. Accessed January 23, 2024. www.genome.gov
 18. Hefti E, Blanco JG. Documenting pharmacogenomic testing with CPT codes. *J AHIMA*. 2016;87(1):56-59. Accessed January 23, 2024. www.pubmed.ncbi.nih.gov
 19. Hicks JK, Bishop JR, Sangkuhl K, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2015;98(2):127-134. doi:10.1002/cpt.147
 20. Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. *J Pers Med*. 2019;9(3):40. doi:10.3390/jpm9030040
 21. Hyperhomocysteinemia: A-0629. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
 22. Kohlmann W, Slavotinek A. Genetic testing. UpToDate. Updated October 7, 2022. Accessed January 23, 2024. www.uptodate.com
 23. Laboratory Requirements, 42 C.F.R. § 493 (2024).
 24. Laboratory Services, OHIO ADMIN. CODE 5160-11-11 (2021).
 25. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Food and Drug Administration. Updated December 21, 2023. Accessed January 23, 2024. www.fda.gov
 26. Managed Care: Provider Network and Contracting Requirements. OHIO ADMIN. CODE 5160-26-05 (2022).
 27. Medical code brief: 0345U-PLA (U codes). Hayes; 2022. Accessed January 23, 2024. www.evidence.hayesinc.com
 28. Methotrexate pharmacogenetics: A-1009. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
 29. *MolDx: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)*. Centers for Medicaid and Medicare Services; 2015. LCD ID L35984. Revised July 20, 2023. Accessed January 23, 2024. www.cms.gov
 30. *MolDx: Molecular Diagnostic Tests (MDT)*. Centers for Medicaid and Medicare Services; 2015. LCD ID L36021. Revised May 4, 2023. Accessed January 23, 2024. www.cms.gov

31. *MolDx: Pharmacogenomics Testing*. Centers for Medicaid and Medicare Services; 2020. LCD ID L38394. Updated August 24, 2023. Accessed January 23, 2024. www.cms.gov
32. *MolDx: Repeat Germline Testing*. Centers for Medicaid and Medicare Services; 2020. LCD ID L38288. Revised December 7, 2023. Accessed January 23, 2024. www.cms.gov
33. Molecular test assessment: GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience). Hayes; 2021. Updated November 13, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
34. National Cancer Institute (NCI). NCI Dictionary of Genetics Terms. National Institute of Health. Accessed January 23, 2024. www.cancer.gov
35. National Center for Biotechnology Information. Genetic testing registry. National Library of Medicine. Accessed January 23, 2024. www.ncbi.nlm.nih.gov
36. *National Correct Coding Initiative Policy Manual For Medicaid Services*. Centers for Medicaid and Medicare Services. Updated January 1, 2024. Accessed January 23, 2024. www.medicare.gov
37. Opioid pharmacogenetics-CYP450 polymorphisms and OPRM1 gene: A-0992. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
38. Pharmacogenetic testing. American Academy of Child and Adolescent Psychiatry. Updated December 2019. Accessed January 23, 2024. www.aacap.org
39. Pharmacogenomic testing for Warfarin response. Centers for Medicaid and Medicare Services; 2009. NCD ID 90.1. Accessed January 23, 2024. www.cms.gov
40. Precision medicine research brief: Genecept Assay (Genomind). Hayes; 2016. Accessed January 23, 2024. www.evidence.hayesinc.com
41. Precision medicine research brief: PGxOne Plus (Admera Health). Hayes; 2017. Accessed January 23, 2024. www.evidence.hayesinc.com
42. Precision medicine research brief: Proove Opioid Risk Test (Proove Biosciences). Hayes; 2016. Accessed January 23, 2024. www.evidence.hayesinc.com
43. Psychotropic medication pharmacogenetics: A-0861. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
44. Psychotropic medication pharmacogenetics-CYP450 polymorphisms: A-0692. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
45. Psychotropic medication pharmacogenetics-gene panels: A-0861. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
46. Raby B. Personalized medicine. UpToDate. Updated September 06, 2023. Accessed January 23, 2024. www.uptodate.com
47. Tacrolimus pharmacogenetics-CYP3A4 and CYP3A5 genes: A-0775. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
48. Tamoxifen pharmacogenetics-CYP2D6 gene: A-0647. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

49. Tantisira K, Weiss S. Overview of pharmacogenomics. Updated December 20, 2023. Accessed January 23, 2024. www.uptodate.com
50. Warfarin pharmacogenetics-CYP2C9, CYP4F2, and VKORC1 genes: A-0587. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com

Approved by Ohio Dept. of Medicaid 02/08/2024.

Archived

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.